Results 51 to 60 of about 102,412 (251)

Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey

Bleeding, Thrombosis and Vascular Biology
Background: a survey was launched to assess the challenges that Italian patients and physicians face with home prophylaxis using low-molecular-weight heparin (LMWH), promoted by the "Arianna Anticoagulazione" Foundation, Bologna, Italy.
Stefania Cavazza, Gualtiero Palareti
doaj   +1 more source

Design and Engineering of an Artificial Bifunctional N‐Deacetylase/N‐Sulfotransferase for the Biosynthesis of N‐Sulfated Heparosan

Advanced Science, EarlyView.
An artificial bifunctional N‐deacetylase/N‐sulfotransferase was engineered in Escherichia coli by combining screened N‐deacetylases with an NST domain. The integrated engineering strategy improved enzyme performance. The optimized enzyme efficiently converted heparosan into N‐sulfated heparosan, addressing a key bottleneck in microbial heparin ...
Xintong Xi, Ruirui Xu, Daoan Wang, Guobin Yin, Xinjing Wang, Haiqin Chen, Guocheng Du, Jian Chen, Zhen Kang   +8 more
wiley   +1 more source

Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism

Thrombosis Journal, 2011
Background The prevention of venous thromboembolism has been identified as a leading priority in hospital safety. Recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include ...
Adiguzel Cafer, Fareed Jawed, Thethi Indermohan   +2 more
doaj   +1 more source

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

Advanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou, Xiaodi Zhao, Xiaochen Pan, Zhiling Ma, Huaqing Cui, Hui Wen, Peng Wang, Xiufeng Liao, Kejie Qin, Yuchen Wang, Li Sheng, Sen Zhang   +11 more
wiley   +1 more source

Risk Factors of Bleeding after Subcutaneous Injection of Low-molecular-weightHeparin in Elderly Patients with Unstable Angina Pectoris and Asthenia

Guoji laonian yixue zazhi
Objective To analyze the risk factors of bleeding after subcutaneous injection of low-molecular-weight heparin in elderly patients with unstable angina pectoris and weakness.
Qi Wu, Meili Ji, Rong Zhang, Danlei Wang, Peipei Xia   +4 more
doaj   +1 more source

Rational Design of Anticoagulant Drugs Using Oligosaccharide Chemistry

CHIMIA, 2011
For a long time, heparin and low molecular weight heparins have been the drugs of choice for the management of thrombosis. Discovery of the antithrombin binding domain in heparin, a critical element in the anticoagulant activity of this ...
Ahmed El Hadri, Maurice Petitou
doaj   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Hepatology, EarlyView., 2022
Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning   +25 more
wiley   +1 more source

Low molecular weight heparin-induced thrombocytopenia management during hemodialysis and cardiac surgery: a case report and literature review

JA Clinical Reports
Background Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy, including low molecular weight heparins (LMWHs) like dalteparin.
Shuto Takada, Shogo Suzuki, Takahiro Tamura   +2 more
doaj   +1 more source

Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells

Brazilian Journal of Medical and Biological Research, 2001
The anticlotting and antithrombotic activities of heparin, heparan sulfate, low molecular weight heparins, heparin and heparin-like compounds from various sources used in clinical practice or under development are briefly reviewed.
H.B. Nader, M.A.S. Pinhal, E.C. Baú, R.A.B. Castro, G.F. Medeiros, S.F. Chavante, E.L. Leite, E.S. Trindade, S.K. Shinjo, H.A.O. Rocha, I.L.S. Tersariol, A. Mendes, C.P. Dietrich   +12 more
doaj   +1 more source